Peptide record

TPDB91257

Lasioglossin - III LL-III LL-III/37 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity modified_plain modified
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91257
Lasioglossin - III LL-III LL-III/37
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb AVPpred-BWR APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 15-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
VNWKKILGKIIKVVK-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
15 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial and Antifungal Antimicrobial Activity
Lasioglossin III and its analogs Lasioglossum laticeps Activity
Evidence Records 8 records
Evidence 1 Activity

Activity

IC50
IC50 = 4±1 µM
Anticancer
4

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 5±1 µM
Anticancer
5

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

IC50
IC50 = 18±4 µM
Anticancer
18

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

IC50
IC50 = 13 µM
Anticancer
13 µM

Target

Colon Cancer
SW
Colon

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

IC50
IC50 = 5±3 µM
Anticancer
5

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 6 Activity

Activity

IC50
IC50= 4±1 µM
Anticancer
4

Target

Leukemia Cancer
CCRF-CEM
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 7 Activity

Activity

IC50
IC50 = 26.36 µM
Anticancer
26.36 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

Not Available
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2023
Evidence 8 Activity

Activity

IC50
IC50 = 7.75 µM
Anticancer
7.75 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

Not Available
Not Available

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2023